NASDAQ:FATE

Fate Therapeutics Stock Earnings Reports

etoro logo Buy FATE
*Your capital is at risk
$0.97
+0.0090 (+0.93%)
At Close: Nov 17, 2025

Fate Therapeutics Earnings Calls

Sep 30, 2025
-$0.270 (6.90%)
Release date Nov 13, 2025
EPS estimate -$0.290
EPS actual -$0.270
EPS Surprise 6.90%
Revenue estimate 1.088M
Revenue actual 1.741M
Revenue Surprise 60.03%
Jun 30, 2025
-$0.290 (17.14%)
Release date Aug 12, 2025
EPS estimate -$0.350
EPS actual -$0.290
EPS Surprise 17.14%
Revenue estimate 1.149M
Revenue actual 1.907M
Revenue Surprise 65.98%
Mar 31, 2025
-$0.320 (17.95%)
Release date May 13, 2025
EPS estimate -$0.390
EPS actual -$0.320
EPS Surprise 17.95%
Revenue estimate 1.184M
Revenue actual 1.629M
Revenue Surprise 37.53%
Dec 31, 2024
-$0.310 (29.55%)
Release date Mar 05, 2025
EPS estimate -$0.440
EPS actual -$0.310
EPS Surprise 29.55%
Revenue estimate 1.569M
Revenue actual 1.86M
Revenue Surprise 18.57%

Last 4 Quarters for Fate Therapeutics

Below you can see how FATE performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.

SIGN UP FREE
or
Creating an account or logging in means you agree to StockInvest.us Terms of Use and Privacy Policy.
Dec 31, 2024 Beat
Release date Mar 05, 2025
Price on release $0.91
EPS estimate -$0.440
EPS actual -$0.310
EPS surprise 29.55%
Date Price
Feb 27, 2025 $1.09
Feb 28, 2025 $1.12
Mar 03, 2025 $1.03
Mar 04, 2025 $0.95
Mar 05, 2025 $0.91
Mar 06, 2025 $1.04
Mar 07, 2025 $1.01
Mar 10, 2025 $0.93
Mar 11, 2025 $0.96
4 days before -16.96%
4 days after 6.05%
On release day 14.90%
Change in period -11.94%
Mar 31, 2025 Beat
Release date May 13, 2025
Price on release $1.00
EPS estimate -$0.390
EPS actual -$0.320
EPS surprise 17.95%
Date Price
May 07, 2025 $1.00
May 08, 2025 $1.03
May 09, 2025 $1.04
May 12, 2025 $1.07
May 13, 2025 $1.00
May 14, 2025 $0.96
May 15, 2025 $1.01
May 16, 2025 $1.07
May 19, 2025 $1.22
4 days before 0%
4 days after 22.00%
On release day -4.00%
Change in period 22.00%
Jun 30, 2025 Beat
Release date Aug 12, 2025
Price on release $0.94
EPS estimate -$0.350
EPS actual -$0.290
EPS surprise 17.14%
Date Price
Aug 06, 2025 $1.04
Aug 07, 2025 $0.98
Aug 08, 2025 $0.92
Aug 11, 2025 $0.94
Aug 12, 2025 $0.94
Aug 13, 2025 $1.13
Aug 14, 2025 $1.07
Aug 15, 2025 $1.09
Aug 18, 2025 $1.20
4 days before -9.97%
4 days after 28.16%
On release day 20.69%
Change in period 15.38%
Sep 30, 2025 Beat
Release date Nov 13, 2025
Price on release $0.99
EPS estimate -$0.290
EPS actual -$0.270
EPS surprise 6.90%
Date Price
Nov 07, 2025 $1.07
Nov 10, 2025 $1.09
Nov 11, 2025 $1.12
Nov 12, 2025 $1.04
Nov 13, 2025 $0.99
Nov 14, 2025 $0.96
Nov 17, 2025 $0.97
4 days before -7.26%
4 days after -1.94%
On release day -2.85%
Change in period -9.07%

Fate Therapeutics Earnings History

Earnings Calendar

FAQ

When is the earnings report for FATE?
Fate Therapeutics (FATE) has scheduled its earnings report for Mar 04, 2026 before the markets open.

What is the FATE price-to-earnings (P/E) ratio?
FATE P/E ratio as of Nov 17, 2025 (TTM) is -0.735.

What is the FATE EPS forecast?
The forecasted EPS (Earnings Per Share) for Fate Therapeutics (FATE) for the first fiscal quarter 2025 is -$0.290.

What are Fate Therapeutics's retained earnings?
On its balance sheet, Fate Therapeutics reported retained earnings of $1.74 million for the latest quarter ending Sep 30, 2025.

What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.

Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.

What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
Click to get the best stock tips daily for free!
ABOUT FATE THERAPEUTICS
Fate Therapeutics
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat mul...
GOLDEN STAR
Ticker Change Signal Date
UNIT
$6.00
4.83% Nov 04
TBPH
$14.14
27.58% Oct 23
A
AMIX
$1.12
2.68% Oct 23
COCO
$40.85
11.21% Oct 23
LAUR
$29.55
1.20% Oct 22

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE